Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Inclusion Criteria:

• Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:

  • Primary refractory disease (no complete response [CR] after ≥ 2 induction therapies)
  • Relapsed disease not in CR after ≥ 1 course of standard reinduction therapy
  • Secondary AML from myelodysplastic syndromes
  • Disease relapsed ≥ 2 months after transplant and no option of donor lymphocyte infusions (e.g., recipients of autologous or umbilical cord blood transplants)
  • Chronic myelogenous leukemia with myeloid blast crisis not in second chronic phase after at least one cycle of standard chemotherapy and imatinib
  • Over 60 years of age with relapse within 6 months after completion of last chemotherapy
  • Over 60 years of age with blast count < 30% within 10 days before study entry
• Related HLA-haploidentical natural killer cell donor available
• No severe organ damage (by clinical or laboratory assessment)
• Performance status 50-100%
• No evidence of active infection on chest X-ray
• No active fungal infection

Exclusion Criteria:

• Active central nervous system (CNS) leukemia
• Pleural effusions large enough to be detectable by chest x-ray
• Pregnant or nursing (positive pregnancy test)
• Fertile patients must use effective contraception
• Less than 60 days since prior transplant
• Less than 3 days since prior prednisone
• Less than 3 days since other prior immunosuppressive medication